Oliver Cornely
🎓 MD @Uniklinik Köln @Uni Köln 🇩🇪 | FECMM, Infectious Diseases | 🔬 Clinical Trialist @CECAD | 📚 Top 1% Cited (Clarivate) | 📍 @DZIF Bonn-Cologne | 💡 37K+ Volunteers (DE) | 🌍 525 Sites | 🎥 IDIM (YouTube)
- Honored to host Prof. Ruoyu Li & Prof. Yinggai Song at our ECMM Excellence Center Cologne. From Cologne Cathedral to TRIO lab, insightful discussions & guided tours. Looking forward to future collaborations!
- At PRISMA Congress, @salmantongarcia.bsky.social presents "The evolving challenge of fungal resistance", highlighting the latest developments and emerging clinical challenges in antifungal resistance. #PRISMA2026 #FungalResistance
- 🎥 New video! Prof. @franbridi.bsky.social introduces rezafungin, a next-generation echinocandin, covering MOA, PK profile & clinical potential in invasive fungal infections. 👉 Watch now: youtu.be/4-rKQjsppOg More videos coming soon!
- New episode of MedFacts with Prof. Schmitt 🎥 Clear, science-based insights into adult vaccination, based on the Vaccitutor Course. Short, accessible, and evidence-based vaccine facts. Watch now ▶️ www.youtube.com/shorts/uTy3t...
- Last week’s #READI General Assembly in Madrid ❄️ Dr. Kerstin Albus and Dr. Johanna Brustkern represented WP5 Clinical Sites #Capability Building, strengthening #clinicaltrial site competencies across Europe to support inclusive, multi-centre research. Great energy – READI is in motion 🚀
- Honored to feature Prof. Arunaloke Chakrabarti in the ISHAM Pioneers in Mycology series. A deep dive into his impact on medical mycology, global challenges, and the future of fungal disease research. Watch the interview: www.isham.org/about-isham/...
- New AGIHO guideline update on G-CSF prophylaxis in adult cancer patients! Evidence-based recommendations incl. immunotherapy settings, biosimilars & risk stratification to support clinical decision-making. 🔗 pubmed.ncbi.nlm.nih.gov/41570611/ @rosannesprute.bsky.social #Oncology #Guidelines
